Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused
by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting …

Controlling the spread of antimalarial drug resistance, especially resistance of P lasmodium
falciparum to artemisinin‐based combination therapies, is a high priority. Available data …

It is widely assumed in genetics that most mutations disrupt metabolism to some extent, and
are consequently likely to be disadvantageous for the organisms that inherit them. This may …

Background Chemotherapy can prompt the evolution of classical drug resistance, but
selection can also favour other parasite traits that confer a survival advantage in the …

Adaptive evolution of malaria parasites to therapy has been very successful. Over just a few
decades, the parasites have developed resistance to all drugs introduced to fight the …

Although the last two decades have seen a substantial decline in malaria incidence and
mortality due to the use of insecticide-treated bed nets and artemisinin combination therapy …

This article outlines genome-scale approaches that can be used to identify mutations in
malaria (Plasmodium) parasites that underlie drug resistance and contribute to treatment …

The evolution of antimalarial drug resistance is often considered to be a single-stage
process in which parasites are either fully resistant or completely sensitive to a drug …

Drug resistance in malaria jeopardizes the most elementary objectives of malaria control–
reducing suffering and eliminating mortality. An important, and so far the only known …

To develop public-health policies that extend the lifespan of affordable anti-malarial drugs
as effective treatment options, it is necessary to understand the evolutionary processes …